Agata Leszek

Agata Leszek

Auto-generated profile, based on publicly available information

Agata Leszek

Wojskowy Szpital Kliniczny z Polikliniką Wrocław, Poland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MLMałgorzata Lubowiecka
Małgorzata Lubowiecka
ASAnna Szeszko
Anna Szeszko
ZLZuzanna Lecyk
Zuzanna Lecyk
ALAgata Leszek
Agata Leszek
NMNatalia Moskwa
Natalia Moskwa
BBBianka A. Błaszkiewicz
Bianka A. Błaszkiewicz
Research objectives: This systematic review aims to assess and summarize the available evidence comparing step-up strategies versus early biologic therapy for pouchitis. The goal is to clarify their relative effectiveness, safety profiles, and impact on clinical outcomes to inform evidence-based treatment algorithms and identify gaps for future research. Methods: A systematic review was conducted using PubMed, Google Scholar, and ResearchGate. Eligible studies included clinical trials, observational studies, systematic reviews, meta-analyses, and international guidelines published after 1990. Search terms combined RPC-IPAA, acute pouchitis, chronic pouchitis, step-up therapy, biologic therapy, antibiotics, immunosuppressants, and advanced therapies. Key findings: Most patients with acute pouchitis treated with antibiotics achieved a short-term clinical response, although relapses and progression to chronic disease were common. Chronic combination antibiotic therapy maintained remission in approximately three-quarters of patients but was associated with bacterial resistance and adverse events. Biologic agents achieved response rates of approximately 60%, while remission remained ≤50%. Vedolizumab and ustekinumab showed higher long-term tolerability and treatment persistence than TNF inhibitors. Evidence of early biologic therapy was limited, and no clear association between early initiation and clinical outcomes was identified. Conclusions: Step-up antibiotic therapy remains justified as the first-line treatment for pouchitis due to its high short-term efficacy. Biologic agents represent a valuable option for chronic or refractory disease but do not appear to be superior to antibiotics as initial treatment. Current evidence does not support routine early biologic therapy for all patients, although selected high-risk groups may benefit. Future prospective studies are needed to define optimal timing of biologic therapy.

30 August 2026 in Archiv Euromedica
Verified
Journal Article
Closed access
MLMałgorzata Lubowiecka
Małgorzata Lubowiecka
ZLZuzanna Lecyk
Zuzanna Lecyk
ALAgata Leszek
Agata Leszek
ASAnna Szeszko
Anna Szeszko
MCMagdalena Cichorzewska
Magdalena Cichorzewska
MSMichał Stermach
Michał Stermach
Background Chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME), is a heterogeneous disorder characterized by persistent fatigue, post-exertional malaise, unrefreshing sleep, pain, cognitive symptoms, and impaired daily functioning. Diagnosis is based on clinical criteria and exclusion of other diseases, while reliable biomarkers and standard treatment are lacking. Aims This narrative review aimed to summarize the reported effects of cognitive behavioral therapy, exercise-based interventions, nutritional supplementation, rituximab, and rintatolimod in patients with CFS. Materials and Methods A structured narrative literature search was performed in PubMed and Google Scholar. ResearchGate was used only to retrieve full-text articles. The search was conducted in June 2026 and covered publications from 2001 to 2025. Of 132 identified publications, 54 were included. Because the studies differed in design, diagnostic criteria, interventions, follow-up duration, and outcome measures, the evidence was synthesized qualitatively. Results Cognitive behavioral therapy appeared to show the most consistent beneficial effects, mainly on fatigue and physical functioning, although complete recovery was uncommon. Exercise-based interventions produced mixed results; self-paced aquatic exercise programs were better tolerated, whereas graded exercise did not consistently outperform comparator interventions and was associated with symptom worsening in some patients. Nutritional interventions showed heterogeneous findings, with reported benefits mainly for CoQ10 plus NADH, selenium, creatine, and combined nutraceutical therapy. Rituximab did not show efficacy in a phase III randomized trial. Rintatolimod showed promising effects on exercise tolerance, but further confirmation is required. Conclusions Cognitive behavioral therapy may help reduce symptoms and improve functioning in selected patients with CFS, but it should not be presented as curative. Exercise programs should be individualized and adapted to the risk of post-exertional malaise. Nutritional supplementation may have an adjunctive role, but evidence remains heterogeneous. Rituximab cannot be recommended for routine use, while rintatolimod remains investigational. Future studies should clarify which patient subgroups may benefit from specific interventions.

27 August 2026 in Archiv Euromedica
Verified
Journal Article
Closed access
ALAgata Leszek
Agata Leszek
MSMichał Stermach
Michał Stermach
ZLZuzanna Lecyk
Zuzanna Lecyk
MLMałgorzata Lubowiecka
Małgorzata Lubowiecka
NMNatalia Moskwa
Natalia Moskwa
BBBianka Błaszkiewicz
Bianka Błaszkiewicz
Background Irritable bowel syndrome (IBS) is a chronic disorder of gut brain interaction in children associated with recurrent abdominal pain, altered bowel habits, psychological comorbidities, impaired daily functioning, and reduced quality of life. Aim This narrative review summarizes current evidence on the pathogenesis, diagnosis, and long term management of pediatric IBS, with emphasis on gut brain interactions, psychosocial factors, recent pediatric guidelines, and pharmacological and non-pharmacological interventions. Materials and Methods PubMed, Embase, Cochrane Library, and Google Scholar were searched for English language publications from 2010 to 2026. The final search was conducted on June 15, 2026. Fifty studies and guidelines were included in the descriptive synthesis. Results Pediatric IBS has a multifactorial pathogenesis involving disturbances in gut brain communication, visceral hypersensitivity, post infectious mechanisms, alterations in the intestinal microbiota, and psychosocial factors. Diagnosis relies on symptom-based criteria, clinical assessment, and evaluation for alarm features; routine extensive testing is discouraged when alarm features are absent. Management should be individualized and may include education of the child and family, dietary measures, psychological interventions, and symptom directed pharmacotherapy. Cognitive behavioural therapy and gut directed hypnotherapy may reduce symptoms and psychological distress in selected children. Evidence for dietary and pharmacological interventions remains heterogeneous, and microbiome profiles are not established diagnostic biomarkers for routine clinical use. Conclusions Pediatric IBS should be diagnosed clinically and managed according to predominant symptoms, disease severity, psychological comorbidities, and daily functioning. Further pediatric studies are needed to clarify the effectiveness, safety, duration, and optimal sequence of interventions.

31 August 2026 in Archiv Euromedica
Verified
Journal Article
Closed access
PKPrzemysław Krukowski
Przemysław Krukowski
ZGZuzanna Gąsior
Zuzanna Gąsior
MGMaria Grabowska
Maria Grabowska
MSMichał Stermach
Michał Stermach
MMMichał Maciejowski
Michał Maciejowski
APAdrianna Przedborska
Adrianna Przedborska
Background Patients with chronic kidney disease (CKD), particularly those with type 2 diabetes (T2D) and albuminuria, remain at substantial risk of kidney disease progression and cardiovascular complications despite established therapy. SGLT2 inhibitors and finerenone act through distinct and potentially complementary mechanisms. Aims To evaluate the mechanisms, clinical effects, and safety of combined SGLT2 inhibitor and finerenone therapy in patients with CKD, particularly those with T2D and albuminuria, and to consider these findings within the broader cardiovascular kidney metabolic (CKM) framework. Materials and Methods A narrative review was conducted using PubMed, Scopus, and Web of Science. Publications available up to June 2026 were considered. The search focused on SGLT2 inhibitors, finerenone, CKD, heart failure, eGFR, albuminuria, and cardiorenal syndrome. After removal of duplicates and application of eligibility criteria, 44 publications were retained for qualitative synthesis. Results SGLT2 inhibitors primarily affect glomerular hemodynamics, natriuresis, and metabolic pathways, whereas finerenone modulates mineralocorticoid receptor mediated inflammatory and fibrotic pathways. The CONFIDENCE trial showed that simultaneous initiation of finerenone and empagliflozin produced a greater reduction in UACR than either monotherapy over 180 days. Meta analytic and observational data suggest potential additional benefits for MAKE, ESRD, some cardiovascular outcomes, and all cause mortality, although these findings vary according to comparator and study design. Hyperkalemia risk may be lower than with finerenone monotherapy but remains higher than with SGLT2 inhibitor monotherapy in some comparisons. An early decline in eGFR was observed, whereas acute kidney injury and symptomatic hypotension were uncommon. Conclusions Combined SGLT2 inhibitor and finerenone therapy is a promising option for carefully selected patients with CKD, T2D, and albuminuria. The strongest randomized evidence concerns reduction in albuminuria, whereas evidence for long term kidney and cardiovascular outcomes and mortality remains limited. Hyperkalemia risk is not eliminated, and regular monitoring of serum potassium and kidney function remains necessary. Extrapolation to the broader CKM population and to patients with heart failure requires further investigation.

21 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
BBBianka Błaszkiewicz
Bianka Błaszkiewicz
KMKatarzyna Marut
Katarzyna Marut
KKKsenia Oksana Kobelak
Ksenia Oksana Kobelak
IBIga Borejszo
Iga Borejszo
MLMałgorzata Lubowiecka
Małgorzata Lubowiecka
ZLZuzanna Lecyk
Zuzanna Lecyk
Obesity and hypothyroidism are among the most prevalent chronic disorders worldwide and frequently coexist in clinical practice. Although hypothyroidism has traditionally been regarded as a contributing factor to weight gain because of its effects on basal metabolic rate and energy expenditure, accumulating evidence suggests that obesity itself may substantially influence thyroid function through endocrine, metabolic, and inflammatory mechanisms. This comprehensive review summarizes current evidence regarding the association between obesity and hypothyroidism, focusing on epidemiological findings, pathophysiological mechanisms, thyroid autoimmunity, metabolic phenotypes, pediatric and adult populations, and therapeutic implications. Evidence from systematic reviews, longitudinal cohort studies, Mendelian randomization analyses, and observational investigations indicates that obesity is associated with an increased prevalence of both overt and subclinical hypothyroidism. Adipose tissue-derived mediators, particularly leptin and pro-inflammatory cytokines, appear to influence the hypothalamic–pituitary–thyroid axis, alter peripheral thyroid hormone metabolism, and promote autoimmune thyroid disease. However, mild elevations of thyroid-stimulating hormone observed in many obese individuals, especially children, often represent adaptive physiological responses rather than permanent thyroid dysfunction and frequently normalize following weight reduction. Current evidence further suggests that improving metabolic health and reducing excess body weight have greater effects on thyroid function than thyroid hormone replacement alone in patients without overt hypothyroidism. Overall, the available literature supports a bidirectional but predominantly obesity-driven relationship between obesity and thyroid dysfunction. Understanding these mechanisms may improve diagnostic accuracy, reduce unnecessary pharmacological treatment, and facilitate individualized management strategies for patients presenting with both conditions.

25 June 2026 in Archiv Euromedica
Verified
Journal Article
Closed access
ALAgata Leszek
Agata Leszek
IPIga Poprawa
Iga Poprawa
MSMichał Stermach
Michał Stermach
NKNina Kubikowska
Nina Kubikowska
ZGZuzanna Gąsior
Zuzanna Gąsior
MLMałgorzata Lubowiecka
Małgorzata Lubowiecka
Background Diabetes mellitus is a chronic metabolic disease associated with ocular complications beyond classical diabetic retinopathy. Long-term diabetes may affect the retinal neurovascular unit, retinal microcirculation, visual function, cornea, ocular surface, lens, optic nerve, and glaucoma-related structures. Some of these abnormalities may occur before clinically visible diabetic retinopathy. Aims The aim of this narrative review was to summarize current evidence on long-term structural and functional ocular changes associated with type 1 and type 2 diabetes mellitus, with emphasis on retinal neurodegeneration, retinal microvascular impairment, functional visual deficits, and selected extraretinal ocular complications. Methods A narrative literature review was conducted using PubMed, Embase, Cochrane Library, and Google Scholar. English-language publications from 2008 to 2026 were considered, and the final search was conducted on April 15, 2026. Search terms included diabetes mellitus, diabetic retinopathy, retinal neurodegeneration, corneal neuropathy, cataract, glaucoma, ocular complications, retina, and visual function. Meta-analyses, systematic reviews, longitudinal prospective studies, cross-sectional studies, and expert opinion articles were included. A total of 230 articles were initially identified, 85 full-text articles were assessed, and 43 key studies were included. Results Long-term diabetes was associated with retinal neurovascular damage, retinal neurodegeneration, retinal microvascular impairment, functional visual abnormalities, and selected extraretinal ocular complications. OCT studies demonstrated thinning of the inner retinal layers, including changes in the ganglion cell complex and retinal nerve fiber layer. OCT angiography may detect reduced macular microvascular density and capillary dropout before classical ophthalmoscopic signs of diabetic retinopathy. ERG, pattern ERG, VEP, and microperimetry may reveal abnormalities in retinal response, neural conduction, and macular sensitivity. Beyond the retina, diabetes was associated with corneal neuropathy, diabetic keratopathy, ocular surface disease, impaired epithelial healing, accelerated cataract formation, optic nerve and functional visual pathway involvement, and increased glaucoma risk. Conclusions Long-term type 1 and type 2 diabetes mellitus is associated with ocular changes beyond classical diabetic retinopathy. Assessment focused only on clinically visible retinopathy may miss earlier structural, microvascular, and functional abnormalities. A multimodal and individualized diagnostic approach may be useful, depending on disease duration, metabolic control, ocular symptoms, clinical findings, and available resources. Further longitudinal studies with standardized outcome measures are needed to clarify early diagnostic markers, risk stratification, and monitoring strategies for diabetes-related ocular disease.